Gland Pharma Receives Customs Order Regarding IGST Demand and Penalties
Gland Pharma Limited has received an order from the Customs Authority pertaining to an Integrated Goods and Services Tax (IGST) demand, including interest and penalties, for the financial years 2020-2021 and 2021-2022. The order was issued by the Principal Commissioner of Customs in Hyderabad.The Order-in-Original, dated July 10, 2026, relates to the availment of IGST benefits amounting to INR. 3,52,93,678/- under Notification No. 18/2015-Cus. The authorities have confirmed a demand of INR. 3,52,93,678/- along with applicable interest, and further imposed a penalty of INR. 3,52,93,678/- under the provisions of the Customs Act, 1962.
The company received the official communication via Speed Post on July 15, 2026.
Order Details
| Particulars | Details |
|---|---|
| Issuing Authority | Principal Commissioner of Customs, Hyderabad, Telangana |
| Order Reference | Order-in-Original No. HYD-CUS-004-COM-26-27 dated 10.07.2026 |
| Disputed IGST Amount | INR. 3,52,93,678/- (plus interest) |
| Penalty Amount | INR. 3,52,93,678/- |
| Period Covered | FY 2020-2021 and FY 2021-2022 |
Company Response
Gland Pharma has stated that, upon assessing the facts and prevailing laws, it believes the IGST demand and penalties levied are not justified. The company is currently in the process of filing an appeal with the appellate authority regarding this matter.The company further noted that based on its internal evaluation, the order is expected to have no material impact on its financial standing, operations, or other business activities.
GLAND Stock Price Movement
Gland Pharma Limited shares rallied 3.29% today to settle at ₹2529.4 in post-market trading. The stock reached its 52-week high during the session on a notable volume of 809,358 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.